321 related articles for article (PubMed ID: 32495250)
1. Theranostics in neuroendocrine tumors: an overview of current approaches and future challenges.
Refardt J; Hofland J; Kwadwo A; Nicolas GP; Rottenburger C; Fani M; Wild D; Christ E
Rev Endocr Metab Disord; 2021 Sep; 22(3):581-594. PubMed ID: 32495250
[TBL] [Abstract][Full Text] [Related]
2. Molecular Imaging in neuroendocrine neoplasias.
Christ E; Wild D; Refardt J
Presse Med; 2022 Jun; 51(2):104115. PubMed ID: 35131317
[TBL] [Abstract][Full Text] [Related]
3. Molecular Imaging of Neuroendocrine Neoplasms.
Refardt J; Hofland J; Wild D; Christ E
J Clin Endocrinol Metab; 2022 Jun; 107(7):e2662-e2670. PubMed ID: 35380158
[TBL] [Abstract][Full Text] [Related]
4. New Directions in Imaging Neuroendocrine Neoplasms.
Refardt J; Hofland J; Wild D; Christ E
Curr Oncol Rep; 2021 Nov; 23(12):143. PubMed ID: 34735669
[TBL] [Abstract][Full Text] [Related]
5. Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms.
Fani M; Peitl PK; Velikyan I
Pharmaceuticals (Basel); 2017 Mar; 10(1):. PubMed ID: 28295000
[No Abstract] [Full Text] [Related]
6. Triple-peptide receptor targeting in vitro allows detection of all tested gut and bronchial NETs.
Reubi JC; Waser B
J Nucl Med; 2015 Apr; 56(4):613-5. PubMed ID: 25698785
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like Peptide-1 Receptor as Emerging Target: Will It Make It to the Clinic?
Wild D; Antwi K; Fani M; Christ ER
J Nucl Med; 2021 Jul; 62(Suppl 2):44S-50S. PubMed ID: 34230073
[TBL] [Abstract][Full Text] [Related]
8. Innovative imaging of insulinoma: the end of sampling? A review.
Christ E; Antwi K; Fani M; Wild D
Endocr Relat Cancer; 2020 Apr; 27(4):R79-R92. PubMed ID: 31951592
[TBL] [Abstract][Full Text] [Related]
9. Multiple endocrine neoplasia type 1 (MEN-1) and neuroendocrine neoplasms (NENs).
Effraimidis G; Knigge U; Rossing M; Oturai P; Rasmussen ÅK; Feldt-Rasmussen U
Semin Cancer Biol; 2022 Feb; 79():141-162. PubMed ID: 33905872
[TBL] [Abstract][Full Text] [Related]
10. Role of PET/CT and Therapy Management of Pancreatic Neuroendocrine Tumors.
Calabrò D; Argalia G; Ambrosini V
Diagnostics (Basel); 2020 Dec; 10(12):. PubMed ID: 33297381
[TBL] [Abstract][Full Text] [Related]
11. Glucose-dependent insulinotropic polypeptide receptors in most gastroenteropancreatic and bronchial neuroendocrine tumors.
Waser B; Rehmann R; Sanchez C; Fourmy D; Reubi JC
J Clin Endocrinol Metab; 2012 Feb; 97(2):482-8. PubMed ID: 22112810
[TBL] [Abstract][Full Text] [Related]
12. Preclinical drug studies in MEN1-related neuroendocrine neoplasms (MEN1-NENs).
Grozinsky-Glasberg S; Lines KE; Avniel-Polak S; Bountra C; Thakker RV
Endocr Relat Cancer; 2020 Sep; 27(9):R345-R355. PubMed ID: 32590358
[TBL] [Abstract][Full Text] [Related]
13. Insulinoma imaging with glucagon-like peptide-1 receptor targeting probe (18)F-FBEM-Cys (39)-exendin-4.
Xu Y; Pan D; Xu Q; Zhu C; Wang L; Chen F; Yang R; Luo S; Yang M
J Cancer Res Clin Oncol; 2014 Sep; 140(9):1479-88. PubMed ID: 24838847
[TBL] [Abstract][Full Text] [Related]
14. New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.
Yin F; Wu ZH; Lai JP
World J Gastroenterol; 2022 May; 28(17):1751-1767. PubMed ID: 35633912
[TBL] [Abstract][Full Text] [Related]
15. Radiopeptide imaging and therapy in Europe.
Ambrosini V; Fani M; Fanti S; Forrer F; Maecke HR
J Nucl Med; 2011 Dec; 52 Suppl 2():42S-55S. PubMed ID: 22144555
[TBL] [Abstract][Full Text] [Related]
16. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting.
Reubi JC; Waser B
Eur J Nucl Med Mol Imaging; 2003 May; 30(5):781-93. PubMed ID: 12707737
[TBL] [Abstract][Full Text] [Related]
17. [
Giovannini E; Giovacchini G; Borsò E; Lazzeri P; Riondato M; Leoncini R; Duce V; Ciarmiello A
Curr Radiopharm; 2019; 12(1):11-22. PubMed ID: 30539709
[TBL] [Abstract][Full Text] [Related]
18. Does somatostatin or gastric inhibitory peptide receptor expression correlate with tumor grade and stage in gut neuroendocrine tumors?
Körner M; Waser B; Reubi JC
Neuroendocrinology; 2015; 101(1):45-57. PubMed ID: 25591947
[TBL] [Abstract][Full Text] [Related]
19. SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) 2014.
Garcia-Carbonero R; JImenez-Fonseca P; Teulé A; Barriuso J; Sevilla I;
Clin Transl Oncol; 2014 Dec; 16(12):1025-34. PubMed ID: 25183048
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study.
Bertherat J; Tenenbaum F; Perlemoine K; Videau C; Alberini JL; Richard B; Dousset B; Bertagna X; Epelbaum J
J Clin Endocrinol Metab; 2003 Nov; 88(11):5353-60. PubMed ID: 14602773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]